|Mr. Anthony S. Marucci M.B.A.||Founder, Pres, CEO & Director||1.06M||N/A||1962|
|Dr. Tibor Keler||Founder, Chief Scientific Officer & Exec. VP||654.91k||N/A||1959|
|Mr. Sam Martin||Sr. VP, CFO, Sec. & Treasurer||542.07k||N/A||1971|
|Ms. Elizabeth Crowley||Chief Product Devel. Officer & Sr. VP||507.24k||N/A||1972|
|Dr. Margo Heath-Chiozzi M.D.||Sr. VP of Regulatory Affairs||548.76k||N/A||1957|
|Ms. Sarah Cavanaugh||Sr. VP of Corp. Affairs & Admin.||N/A||N/A||1975|
|Patrick Till||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Freddy A. Jimenez Esq.||Sr. VP & Gen. Counsel||N/A||N/A||1969|
|Dr. Ronald A. Pepin||Chief Bus. Officer & Sr. VP||N/A||N/A||1956|
|Dr. Richard M. Wright Ph.D.||Chief Commercial Officer & Sr. VP||N/A||N/A||1964|
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 2. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 1; Compensation: 5.